Clomi-Med, Clomifene Citrate, 50 mg, 60 Tabs

CLOMI-MED 50 mg by Bioniche Pharma contains Clomiphene Citrate, a synthetic non-steroidal selective estrogen receptor modulator featuring dual estrogenic agonist and antagonist properties. Engineered by Bioniche Pharma for targeted receptor binding, Bioniche Pharma CLOMI-MED competitively displaces endogenous circulating estrogens at the hypothalamic level to stimulate gonadotropin secretion.

CLINICAL PHARMACOLOGY & CHARACTERISTICS

As a selective estrogen receptor modulator, Clomiphene Citrate in Bioniche Pharma CLOMI-MED exhibits tissue-specific antagonist or agonist activity depending on target organ physiology. By blocking estrogenic negative feedback loops at the hypothalamus and anterior pituitary gland, it triggers an upregulation in the synthesis and release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), thereby fostering ovarian follicular maturation and triggering ovulation.

INDICATIONS & CLINICAL USE

• Treatment of ovulatory dysfunction and anovulatory infertility in female patients seeking pregnancy (including individuals diagnosed with polycystic ovary syndrome / PCOS) using Bioniche Pharma CLOMI-MED protocols.
• Therapeutic induction of ovulation following thorough gynecological diagnostic evaluation to rule out primary organic or systemic impediments to conception under Bioniche Pharma medical supervision.

DOSAGE & ADMINISTRATION

Treatment protocols for CLOMI-MED by Bioniche Pharma must be individually calculated and monitored under direct medical direction. Dosing regimens typically consist of cyclical treatment courses initiated on specified days of the menstrual cycle, with dosage adjustments titrated according to individual ovarian response and diagnostic monitoring.

ADVERSE REACTIONS & PRECAUTIONS

Adverse effects observed during Bioniche Pharma CLOMI-MED therapy are generally dose-dependent and reversible upon treatment discontinuation:

• Ovarian Effects: Reversible ovarian enlargement, pelvic discomfort, or functional ovarian cyst formation associated with Bioniche Pharma CLOMI-MED administration.
• Ocular Disturbances: Transient, dose-dependent visual symptoms including blurred vision, scotomas, or photophobia. Immediate discontinuation of therapy is recommended if visual impairment occurs during Bioniche Pharma treatment.
• Vasomotor & Abdominal Symptoms: Hot flashes, abdominal distension, bloating, and generalized pelvic distress reported during Bioniche Pharma CLOMI-MED therapy.

STORAGE & HANDLING

Store Bioniche Pharma CLOMI-MED in a dry, cool location protected from direct sunlight, elevated heat, and atmospheric humidity. Keep strictly out of the reach and sight of children.